Search results
Results From The WOW.Com Content Network
Conversely, central nervous system-related benefits of beta blockers may include prevention and treatment of migraine, essential tremor, akathisia, anxiety, post-traumatic stress disorder, aggression, and obsessive–compulsive disorder. [76] Most beta blockers are lipophilic and can cross into the brain, but there are a number of exceptions. [76]
Ebivol (Nebivolol) tablets. Nebivolol is a beta blocker used to treat high blood pressure and heart failure. [5] As with other β-blockers, it is generally a less preferred treatment for high blood pressure. [6]
Carvedilol, sold under the brand name Coreg among others, is a beta blocker medication, that may be prescribed for the treatment of high blood pressure (hypertension) and chronic heart failure with reduced ejection fraction (also known as HFrEF or systolic heart failure).
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]
[4] Weight reduction – through physical activity and dietary modification, as obesity is a risk factor for heart failure and left ventricular hypertrophy. Effective weight management has been shown to significantly improve the heart's functional status and reduce the risk of all-cause mortality. [5]
The first large study to show a mortality benefit from antihypertensive treatment was the VA-NHLBI study, which found that chlorthalidone was effective. [50] The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that chlorthalidone (a thiazide-like diuretic) was as effective ...
ATC code C07 Beta blocking agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Other serious side effects may include QT prolongation, heart failure, or bronchospasm. [4] Sotalol is a non-selective β-adrenergic receptor blocker which has both class II and class III antiarrhythmic properties. [1] Sotalol was first described in 1964 and came into medical use in 1974. [5] It is available as a generic medication. [4]